Drug Development

Clinical Trials Regulatory Approval Market Competition Oncology Market Launches Pharmaceutical Research Market Trends Research and Development Regulatory Affairs Clinical Research

Jazz Pharmaceuticals to Buy Actio Biosciences for $820 Million

The deal strengthens Jazz’s rare-epilepsy pipeline by adding ABS-1230, an oral precision therapy now in a Phase Ib/IIa registrational trial.

Dupixent Surge Lets Sanofi Reset Strategy as Regeneron Posts Strong Quarter

Lilly to Acquire AtaiBeckley in Deal Valued Up to $3.8 Billion

Zymeworks to Buy Theravance for $929 Million

Lilly Wins Exclusive License to Ascidian RNA Exon-Editing Platform for Kidney Diseases

HCW Biologics Prices Roughly $4 Million At‑The‑Market Private Placement

HCW Biologics Posts Surprise Q1 Profit on Trimmune Deal as Listing Risk Lingers

Zydus to Buy Assertio for $166.4 Million in All-Cash Deal

Cellular Intelligence Takes Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy

SIGA Expects $13 Million TPOXX Delivery in Q2 After Quiet Start to 2026

Regeneron and Telix Form 50/50 Partnership to Develop Targeted Radiopharmaceuticals

Immutep Halts Phase III Lung Cancer Trial After Futility Call as Shares Crash

Astellas–Vir Prostate Cancer Alliance Launches With New Data as VIR Stock Surges

Pfizer to Commercialize Sciwind’s GLP-1 Ecnoglutide in China Under Exclusive License

Barclays Starts Merck at Overweight on 2026 Pipeline Catalysts as WSJ Reports Business Split Plan

FDA Approves Vanda’s Bysanti for Bipolar I Mania and Schizophrenia

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

Zydus to Pay $120 Million to Settle Astellas Mirabegron Patent Case, Continue U.S. Generic Sales

Takeda Strikes Multi-Year AI Drug Discovery Pact With Iambic Worth Over $1.7 Billion

Novo Nordisk Sees Up to 13% Drop in 2026 Profit and Sales After 'Unprecedented' U.S. Price Squeeze